Ascendis Pharma, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Palo Alto CA United States (2006)

Organization Overview

First Clinical Trial
2009
NCT01010425
First Marketed Drug
2021
lonapegsomatropin
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Ascendis Pharma | Ascendis Pharma A/S | Ascendis Pharma A/S European Medical Monitor/Medical Expert | Ascendis Pharma A/S North American Medical Monitor/Medical Expert | Ascendis Pharma Bone Diseases A/S | ASCENDIS PHARMA ENCOCRINOLOGY DIV A/S | Ascendis Pharma Endocrinology Division A/S | Ascendis Pharma Growth Disorders A/S | Ascendis Pharma Inc. | Ascendis Pharma, Inc. | Ascendis Pharma Oncology Division A/S

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Achondroplasia (Phase 2)

Dwarfism, Pituitary (Phase 3)

Endocrine System Diseases (Phase 3)

Hypoparathyroidism (Phase 2)

Parathyroid Diseases (Phase 2)

Pituitary Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 16
  • # of Trial APIs: 13